[Metabolic effects and general side effects in the treatment of endometriosis with an LHRH agonist].
Between 1983 and 1986 40 patients were treated for external genital endometriosis with the LHRH agonist buserelin. Ovarian suppression was achieved for a period of six months with a dose of 900 to 1,800 mcg per day. In addition to gynecological findings, liver and kidney function and lipid metabolism were checked prior to treatment and at regular intervals during treatment. No deviations from normal ranges were found. The general side effects observed during treatment were as a rule attributable to the buserelin-induced relative estrogen deficiency. The efficacy of the medication in the treatment of endometriosis was demonstrated by control pelviscopy. Since no undesirable metabolic side effects have so far been observed with buserelin, it may be considered an effective new alternative treatment for endometriosis.
D000328:Adult; D002064:Buserelin / Q000009:adverse effects* / Q000627:therapeutic use; D004715:Endometriosis / Q000188:drug therapy*; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D005833:Genital Neoplasms, Female / Q000188:drug therapy*; D006801:Humans
D002064:Buserelin
Metabolische Effekte und allgemeine Nebenwirkungen bei Endometriosebehandlung mit einem LHRH-Agonisten.